Say hello to MassDevice +3, a bite-sized view of the top three med-tech stories of the day. This feature of MassDevice.com’s coverage highlights our 3 biggest and most influential stories from the day’s news to make sure you’re up to date on the headlines that continue to shape the medical device industry.
If you read nothing else today, make sure you’re still in the know with MassDevice +3.
A rating agency specializing in evaluating risky investments added Boston Scientific (NYSE:BSX) to its "Risk List," citing the ongoing fallout from its ill-starred Guidant buyout, its accounting and governance practices and how it pays its executives.
Opponents of the 2.3% medical device tax may have found some momentum in the GOP-led U.S. House of Representatives, but efforts in the U.S. Senate are moving much slower.
Former Spectranetics (NSDQ:SPNC) CEO John Schulte faces up to 5 years in prison and up to $250,000 in fines after a federal jury in Colorado convicted him on a single count of lying to federal investigators about his role in charges that the company illegally imported laser medical devices for a clinical trial.